Samtidig administration af nelfinavir og en kraftig CYP3A- hæmmer, ketoconazol, resulterede i en stigning på 35% af nelfinavirs plasma AUC.
Metabolic enzyme inhibitors: co-administration of nelfinavir and a strong inhibitor of CYP3A, ketoconazole, resulted in a 35% increase in nelfinavir plasma AUC.